Tri-Lo-Sprintec(Norgestimate-Ethinyl Estradiol)
TEVA
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Teva Pharmaceutical Industries Limited
$4,981
Medicare cost, 2024
$4,981
Medicare cost, 2024
Medicare drug plans spent $4,981 on Tri-Lo-Sprintec (norgestimate-ethinyl estradiol) in 2024, for 213 prescriptions and refills filled by 134 patients. Spending fell 95% from 2023 to 2024. It is made by Teva Pharmaceutical Industries Limited (TEVA).
Medicare cost, 2024
$4,981
-95.4% from 2023
Prescriptions
213
$23.38 per claim
Patients
134
138 prescribers
Total spending, 2024
$4,981
$37.17 per patient
Questions and answers
How much does Medicare spend on Tri-Lo-Sprintec?
Medicare prescription drug plans paid $4,981 for Tri-Lo-Sprintec in 2024, for 213 prescriptions and refills to 134 patients (down 95.4% from 2023). The average cost per claim was $23.38.
Which state spends the most on Tri-Lo-Sprintec?
New York had the highest Medicare cost for Tri-Lo-Sprintec in 2024: $565 for 30 claims, followed by California ($538).
Who makes Tri-Lo-Sprintec?
Tri-Lo-Sprintec is made by Teva Pharmaceutical Industries Limited (TEVA), listed in the Medicare spending data as Teva USA.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Tri-Lo-Sprintec was $4,981 in 2024, after a high of $236K in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 1,593 | 5,799 | 1,436 | $177K |
| 2023 | 998 | 3,609 | 892 | $108K |
| 2024 | 138 | 213 | 134 | $4,981 |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Teva USA | 213 | $4,981 |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 2
- RxNorm concept IDs
- 578732, 748797, 749155, 749156, 749157
- Application numbers
- ANDA076784
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 4,621 side-effect reports named norgestimate and ethinyl estradiol, the active ingredient of Tri-Lo-Sprintec (reports from 2004 on). 1,865 of them (40.4%) were serious, 43 named a death and 676 named a hospital stay. The reactions named most often were nausea, headache and drug ineffective. 1,207 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
4,621
187 in 2025 (-31.3% from 2024)
Serious
40.4%
1,865 reports
Deaths named
43
0.9% of reports
Hospital stays
676
14.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Tri-Lo-Sprintec?
4,621 reports from 2004 through September 2026 named norgestimate and ethinyl estradiol, the active ingredient of Tri-Lo-Sprintec. 1,865 of them (40.4%) were serious, 43 named a death and 676 named a hospital stay.
What are the most reported side effects of Tri-Lo-Sprintec?
422 reports named nausea, the reaction named most often, followed by headache (284) and drug ineffective (269). In the last 5 years the reaction named most often was nausea (104 reports). A report can name several reactions.
How many side-effect reports named Tri-Lo-Sprintec in 2025?
187 reports were received in 2025 (-31.3% from 2024). 2026 so far: 171 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Tri-Lo-Sprintec caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Tri-Lo-Sprintec caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with norgestimate and ethinyl estradiol: Sprintec, Tri-Sprintec, Estarylla, Mili, Tri-Lo-Mili, Tri-Estarylla, Mono-Linyah, Tri-Lo-Marzia
- Makers on the stock market:
AUROPHARMA.NS
LUPIN.NS
TEVA·AUROPHARMA.NS drug pipeline - Drug approvals (13 approvals on file for norgestimate and ethinyl estradiol) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (norgestimate and ethinyl estradiol) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.